Omiganan
Phase 2Small molecule
Omiganan is one of 70 small molecule programs targeting Rosacea. It is currently in Phase 2.
3
Indications
8
Total Trials
0
Active Trials
69
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Bepreve
BBausch Health Americas, Inc.
Phase 3
Broncho-Vaxom
OOM Pharma SA
Phase 3
GR1802
GGenrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 3
LNK01001
LLynk Pharmaceuticals Co., Ltd
Phase 3
EBGLYSS
Eli LillyPreclinical
Cibinqo
PfizerPreclinical
Ketotifen Fumarate
Tanabe Pharma CorporationPhase 3
Prograf
VVeloxis Pharmaceuticals
Preclinical
Eucrisa
WWake Forest University Health Sciences
Phase 3
MSRD-100
MMerz North America, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Safety and Efficacy2 trials
IgAN2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Omiganan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMaruho Co., Ltd.